An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes

BMC Biotechnology

Volumn 7, Issue , 2007, Pages

  Khanam, Saima ^a   Rajendra, Pilankatta ^a   Khanna, Navin ^a   Swaminathan, Sathyamangalam ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE; SEROTYPES; VIRAL DISEASE;

ANTIGENS; DRUG INTERACTIONS; IMMUNIZATION; VACCINES; VIRUSES;

IMMUNOLOGY;

ADENOVIRUS VECTOR; DENGUE VACCINE; NEUTRALIZING ANTIBODY; PLASMID VECTOR; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CHIMERA; CONTROLLED STUDY; DENGUE; DENGUE VIRUS; DNA VECTOR; DRUG POTENCY; DRUG TARGETING; HUMAN; HUMAN CELL; IMMUNOREGULATION; MOUSE; NONHUMAN; PROTEIN DOMAIN; SEROTYPE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS INTERFERENCE; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN;

ADENOVIRIDAE; ANIMALS; CELLS, CULTURED; DENGUE VACCINES; DENGUE VIRUS; GENETIC VECTORS; IMMUNITY, INNATE; MICE; PLASMIDS; SEROTYPING; T-LYMPHOCYTES; VIRAL INTERFERENCE;

ADENOVIRIDAE; DENGUE VIRUS; DENGUE VIRUS GROUP; FLAVIVIRIDAE;

EID: 33847642682     PISSN: None     EISSN: 14726750     Source Type: Journal    
DOI: 10.1186/1472-6750-7-10     Document Type: Article

References (51)

1. Gibbons RV Vaughn DW Dengue: An escalating problem Brit Med J 2002 324 1563-1566 1123504 12089096 10.1136/bmj.324.7353.1563
2. Gubler DJ Dengue and dengue haemorrhagic fever Clin Microbiol Rev 1998 11 480-496 88892 9665979
3. Guzmán MG Kouri G Dengue: An update Lancet Infect Dis 2002 2 33-42 10.1016/S1473-3099(01)00171-2 11892494
4. Rothman AL Dengue: Defining protective versus pathologic immunity J Clin Invest 2004 113 946-951 379334 15057297 10.1172/JCI200421512
5. Stephenson JR Understanding dengue pathogenesis: Implications for vaccine design Bull WHO 2005 83 308-314 15868023
6. Innis BL Antibody responses to dengue virus infection Dengue and Dengue Hemorrhagic Fever Wallingford, UK: CAB International Gubler DJ, Kuno G 1997 221-243
7. Kurane I Ennis FA Immunopathogenesis of dengue virus infections Dengue and Dengue Hemorrhagic Fever Wallingford, UK: CAB International Gubler DJ, Kuno G 1997 273-290
8. Mongkolsapaya JW Dejnirattisai W Xu XN Vasanawathana S Tangthawornchaikul N Chairunsri A Sawasdivorn S Duangchinda T Dong T Rowland-Jones S Yenchitsomanus PT McMichael A Malasit P Screaton G Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever Nat Med 2003 9 921-927 10.1038/NM887 12808447
9. Halstead SB Deen J The future of dengue vaccines Lancet 2002 360 1243-1245 10.1016/S0140-6736(02)11276-1 12401270
10. Hombach J Barrett AD Cardosa MJ Deubel V Guzman M Kurane I Roehrig JT Sabchareon A Kieny MP Meeting report "Review on flavivirus vaccine development: Proceedings of a meeting jointly organized by the World Health Organization and the Thai ministry of public health", 26-27 April Bangkok, Thailand Vaccine 2005 23 2689-2695 10.1016/ j.vaccine.2004.11.040 15841565
11. Apt D Raviprakash K Brinkman A Semyonov A Yang S Skinner C Diehl L Lyons R Porter K Punnonen J Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen Vaccine 2006 24 335-344 10.1016/j.vaccine.2005.07.100 16125280
12. Konishi E Kosugi S Imoto J Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice Vaccine 2006 24 2200-2207 10.1016/j.vaccine.2005.11.002 16316713
13. Mota J Acosta M Argotte R Figueroa R Méndez A Ramos C Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein Vaccine 2005 23 3469-3476 10.1016/j.vaccine.2004.12.028 15837370
14. Raviprakash K Apt D Brinkman A Skinner C Yang S Dawes G Ewing D Wu SJ Bass S Punnonen J Porter K A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques Virology 2006 353 166-173 10.1016/j.virol.2006.05.005 16814355
15. Simmons M Porter KR Hayes CG Vaughn DW Putnak R Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques J Virol 2006 80 9577-9585 1617260 16973561 10.1128/JVI.00284-06
16. Hermida L Bernardo L Martín J Alvarez M Prado I López C de la Sierra BC Martínez R Rodríguez R Zulueta A Pérez AB Lazo L Rosario D Guillén G Guzmán M A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates Vaccine 2006 24 3165-3171 10.1016/j.vaccine.2006.01.036 16490289
17. Bhamarapravati N Sutee Y Live attenuated tetravalent dengue vaccine Vaccine 2000 18 44-47 10.1016/S0264-410X(00)00040-2 10821973
18. Kanesa-thasan N Sun W Kim-Ahn G Van Albert S Putnak JR King A Raengsakulsrach B Christ-Schmidt H Gilson K Zahradnik JM Vaughn DW Innis BL Saluzzo JF Hoke CH Jr Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers Vaccine 2001 19 3179-3188 10.1016/S0264-410X(01)00020-2 11312014
19. Kanesa-Thasan N Edelman R Tacket CO Wasserman SS Vaughn DW Coster TS Kim-Ahn GJ Dubois DR Putnak JR King A Summers PL Innis BL Eckels KH Hoke CH Jr Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: Selection of safe and immunogenic monovalent vaccines Am J Trop Med Hyg 2003 69 Suppl 6 17-23
20. Edelman R Wasserman SS Bodison SA Putnak RJ Eckels KH Tang D Kanesa-Thasan N Vaughn DW Innis BL Sun W Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine Am J Trop Med Hyg 2003 69 Suppl 6 48-60
21. Sabchareon A Lang J Chanthavanich P Yoksan S Forrat R Attanath P Sirivichayakul C Pengsaa K Pojjaroen-Anant C Chokejindachai W Jagsudee A Saluzzo JF Bhamarapravati N Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: Role of serotype concentration, ratio, and multiple doses Am J Trop Med Hyg 2002 66 264-272 12139219
22. Sabchareon A Lang J Chanthavanich P Yoksan S Forrat R Attanath P Sirivichayakul C Pengsaa K Pojjaroen-Anant C Laurent C Saluzzo JF Bhamarapravati N Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children Pediatr Infect Disease J 2004 23 99-109 10.1097/01.inf.0000109289.55856.27
23. Kitchener S Nissen M Nasveld P Forrat R Yoksan S Lang J Saluzzo JF Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults Vaccine 2006 24 1238-1241 10.1016/j.vaccine.2005.09.029 16213632
24. Guirakhoo F Weltzin R Chambers TJ Zhang ZX Soike K Ratterree M Arroyo J Georgakopoulos K Catalan J Monath TP Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in non-human primates J Virol 2000 74 5477-5485 112032 10823852 10.1128/ JVI.74.12.5477-5485.2000
25. Guirakhoo F Arroyo J Pugachev KV Miller C Zhang ZX Weltzin R Georgakopoulos K Catalan J Ocran S Soike K Ratterree M Monath TP Construction, safety, and immunogenicity in nonhuman primates of a yellow fever-dengue virus tetravalent vaccine J Virol 2001 75 7290-7304 114964 11462001 10.1128/JVI.75.16.7290-7304.2001
26. Guirakhoo F Pugachev K Arroyo J Miller C Zhang ZX Weltzin R Georgakopoulos K Catalan J Ocran S Draper K Monath TP Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: Genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates Virology 2002 298 146-159 10.1006/viro.2002.1462 12093182
27. Guirakhoo F Pugachev K Zhang Z Myers G Levenbook I Draper K Lang J Ocran S Mitchell F Parsons M Brown N Brandler S Fournier C Barrere B Rizvi F Travassos A Nichols R Trent D Monath T Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates J Virol 2004 78 4761-4775 387722 15078958 10.1128/ JVI.78.9.4761-4775.2004
28. IVR/WHO document, April 2005: New vaccines against infectious diseases: research and development status, updated February 2006 http://www.who.int/entity/vaccine_research/documents/en/Status_Table.pdf
29. Blaney JE Jr Hanson CT Firestone CY Hanley KA Murphy BR Whitehead SS Genetically modified, live attenuated dengue virus type 3 vaccine candidates Am J Trop Med Hyg 2004 71 811-821 15642976
30. Blaney JE Jr Matro JM Murphy BR Whitehead SS Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in Rhesus monkeys J Virol 2005 79 5516-5528 1082773 15827166 10.1128/JVI.79.9.5516-5528.2005
31. Swaminathan S Khanna N Viral vaccines for dengue: The present and the future WHO Den Bull 2003 27 181-191 http://www.searo.who.int/LinkFiles/ Dengue_Bulletin_Volume_27_ch25.pdf
32. Pugachev KV Guirakhoo F Trent DW Monath TP Traditional and novel approaches to flavivirus vaccines Intl J Parasitol 2003 33 567-582 10.1016/S0020-7519(03)00063-8
33. Zhou H Deem MW Sculpting the immunological response to dengue fever by polytopic vaccination Vaccine 2006 24 2451-2459 10.1016/ j.vaccine.2005.12.031 16417956
34. Chen Y Maguire T Hileman RE Fromm JR Esko JD Linhardt RJ Marks RM Dengue virus infectivity depends on envelope protein binding to target cell heparin sulfate Nat Med 1997 3 866-871 10.1038/nm0897-866 9256277
35. Mégret F Hugnot JP Falconar A Gentry MK Morens DM Murray JM Schlesinger J Wright PJ Young P van Regenmortel MHV Deubel V Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue envelope glycoprotein Virology 1992 187 480-491 10.1016/0042-6822(92)90450-4 1372140
36. Roehrig JT Bolin RA Kelly RG Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica Virology 1998 246 317-328 10.1006/viro.1998.9200 9657950
37. Crill WD Roehrig RT Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells J Virol 2001 75 7769-7773 115016 11462053 10.1128/JVI.75.16.7769-7773.2001
38. Simmons M Nelson WM Wu SJL Hayes CG Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice Am J Trop Med Hyg 1998 58 655-662 9598457
39. Simmons M Murphy GS Hayes CG Short report: Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine Am J Trop Med Hyg 2001 65 159-161 11508393
40. Hung JJ Hsieh MT Young MJ Kao CL King CC Chang W An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells J Virol 2004 78 378-388 303388 14671119 10.1128/JVI.78.1.378-388.2004
41. Jaiswal S Khanna N Swaminathan S High-level expression and one-step purification of recombinant dengue virus type 2 envelope domain III protein in Escherichia coli Protein Exp Purif 2004 33 80-91 10.1016/ j.pep.2003.09.009
42. Khanam S Khanna N Swaminathan S Induction of antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors Vaccine 2006 24 6513-6525 10.1016/ j.vaccine.2006.06.031 16860446
43. Khanam S Etemad B Khanna N Swaminathan S Induction of neutralizing antibodies specific to dengue virus serotypes 2 and 4 by a bivalent antigen composed of linked envelope domains III of these two serotypes Am J Trop Med Hyg 2006 74 266-277 16474083
44. Trirawatanapong T Chandran B Putnak R Padmanabhan R Mapping of a region of dengue virus type-2 glycoprotein required for binding by a neutralizing monoclonal antibody Gene 1992 116 139-150 10.1016/ 0378-1119(92)90509-N 1634111
45. Jaiswal S Khanna N Swaminathan S Replication-defective adenoviral vaccine vector for the induction of immune responses to dengue virus type 2 J Virol 2003 77 12907-12913 262593 14610213 10.1128/ JVI.77.23.12907-12913.2003
46. Shiver JW Emini EA Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors Annu Rev Med 2004 55 355-372 10.1146/annurev.med.55.091902.104344 14746526
47. Sullivan NJ Sanchez A Rollin PE Yang ZY Nabel GJ Development of a preventive vaccine for Ebola virus infection in primates Nature 2000 408 605-609 10.1038/35046108 11117750
48. Men R Wyatt L Tokimatsu I Arakaki S Shameem G Elkins R Chanock R Moss B Lai CJ Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue virus type 2 challenge Vaccine 2000 18 3113-3122 10.1016/S0264-410X(00)00121-3 10856791
49. Delenda C Staropoli I Frenkiel MP Cabanié L Deubel V Analysis of C-terminally truncated dengue 2 and dengue 3 virus envelope glycoproteins: Processing in insect cells and immunogenic properties in mice J Gen Virol 1994 75 1569-1578 8021588
50. Putnak RP Feighny R Burrous J Cochran M Hackett C Smith G Hoke C Dengue-1 virus envelope glycoprotein gene expressed in recombinant baculovirus elicits virus-neutralizing antibody in mice and protects them from virus challenge Am J Trop Med Hyg 1991 45 159-167 1877710
51. He TC Zhou S DaCosta LT Yu J Kinzler KW Vogelstein B A simplified system for generating recombinant adenoviruses Proc Natl Acad Sci USA 1998 95 2509-2514 19394 9482916 10.1073/pnas.95.5.2509